Pubblicazioni scientifiche

Rizzo A.; Santoni M.; Mollica V.; Logullo F.; Rosellini M.; Marchetti A.; Faloppi L.; Battelli N.; Massari F., Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study, «EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY», 2021, 17, pp. 1455 - 1466 [Articolo in rivista]

Santoni M.; Massari F.; Montironi R.; Battelli N., Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages, «BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER», 2021, 1876, pp. 188547 - 188551 [Articolo in rivista]

Santoni M.; Miccini F.; Cimadamore A.; Piva F.; Massari F.; Cheng L.; Lopez-Beltran A.; Montironi R.; Battelli N., An update on investigational therapies that target STAT3 for the treatment of cancer, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2021, 30, pp. 245 - 251 [Articolo in rivista]

Rizzo A.; Rosellini M.; Marchetti A.; Mollica V.; Massari F., Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence, «IMMUNOTHERAPY», 2021, 13, pp. 685 - 692 [Articolo in rivista]

Marchetti A.; Rosellini M.; Rizzo A.; Mollica V.; Battelli N.; Massari F.; Santoni M., An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma, «EXPERT OPINION ON PHARMACOTHERAPY», 2021, 22, pp. 2323 - 2336 [Articolo in rivista]

Massari F.; Rizzo A.; Mollica V.; Santoni M., A brand-new CAR for macrophages: Is it time to fire up the engines of a new era for the treatment of renal cell carcinoma?, «FUTURE ONCOLOGY», 2021, 17, pp. 1839 - 1841 [Articolo in rivista]

Rizzo A.; Mollica V.; Santoni M.; Massari F., Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis, «EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY», 2021, 15, pp. 1225 - 1232 [Articolo in rivista]

Cimadamore A.; Cheng L.; Massari F.; Santoni M.; Pepi L.; Franzese C.; Scarpelli M.; Lopez-Beltran A.; Galosi A.B.; Montironi R., Circulating tumor dna testing for homology recombination repair genes in prostate cancer: From the lab to the clinic, «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2021, 22, pp. 1 - 15 [Articolo in rivista] Open Access

Santoni M.; Cimadamore A.; Massari F.; Sorgentoni G.; Cheng L.; Lopez-Beltran A.; Battelli N.; Montironi R., Narrative review: Predicting future molecular and clinical profiles of prostate cancer in the United States, «TRANSLATIONAL ANDROLOGY AND UROLOGY», 2021, 10, pp. 1562 - 1568 [Articolo in rivista] Open Access

Cimadamore A.; Cheng L.; Scarpelli M.; Lopez-Beltran A.; Mollica V.; Montironi R.; Massari F., Re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76: Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation, «EUROPEAN UROLOGY», 2021, 79, pp. 17 - 19 [Articolo in rivista]

Lopez-Beltran A.; Cimadamore A.; Blanca A.; Massari F.; Vau N.; Scarpelli M.; Cheng L.; Montironi R., Immune checkpoint inhibitors for the treatment of bladder cancer, «CANCERS», 2021, 13, pp. 1 - 16 [Articolo in rivista] Open Access

Montironi R.; Cheng L.; Cimadamore A.; Mazzucchelli R.; Scarpelli M.; Santoni M.; Massari F.; Lopez-Beltran A., Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups?, «TRANSLATIONAL ANDROLOGY AND UROLOGY», 2021, 10, pp. 1530 - 1540 [Articolo in rivista] Open Access

Cimadamore A.; Cheng L.; Scarpelli M.; Massari F.; Mollica V.; Santoni M.; Lopez-Beltran A.; Montironi R.; Moch H., Towards a new WHO classification of renal cell tumor: What the clinician needs to know-a narrative review, «TRANSLATIONAL ANDROLOGY AND UROLOGY», 2021, 10, pp. 1506 - 1520 [Articolo in rivista] Open Access

Basso U.; Facchinetti A.; Rossi E.; Maruzzo M.; Conteduca V.; Aieta M.; Massari F.; Fraccon A.P.; Mucciarini C.; Sava T.; Santoni M.; Pegoraro C.; Durante E.; Nicodemo M.; Perin A.; Bearz A.; Gatti C.; Fiduccia P.; Diminutto A.; Barile C.; De Giorgi U.; Zamarchi R.; Zagonel V., Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial, «THE ONCOLOGIST», 2021, 26, pp. 740 - 750 [Articolo in rivista]

Rizzo A.; Mollica V.; Massari F., Adjuvant immunotherapy in muscle-invasive urothelial carcinoma, «THE LANCET ONCOLOGY», 2021, 22, pp. 237 - 237 [Articolo in rivista]

Cimadamore A.; Rizzo A.; Mollica V.; Massari F.; Lopez-Beltran A.; Scarpelli M.; Cheng L.; Santoni M.; Montironi R., An update on immunotherapy in uro-oncology, «EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT», 2021, 6, pp. 229 - 233 [Articolo in rivista]

Santoni M.; Massari F.; Santoni G.; Cimadamore A.; Montironi R.; Battelli N., Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy, «EUROPEAN UROLOGY», 2021, 79, pp. 887 - 889 [Articolo in rivista]

Aurilio G.; Santoni M.; Massari F.; Cimadamore A.; Rizzo A.; Mollica V.; Verri E.; Battelli N.; Montironi R., Metabolomic profiling in renal cell carcinoma patients: News and views, «CANCERS», 2021, 13, pp. 1 - 11 [Articolo in rivista] Open Access

Santoni M.; Massari F.; Bracarda S.; Procopio G.; Milella M.; De Giorgi U.; Basso U.; Aurilio G.; Incorvaia L.; Martignetti A.; Rizzo M.; Carteni G.; Grande E.; Matrana M.R.; Crabb S.J.; Vau N.; Sorgentoni G.; Cimadamore A.; Montironi R.; Battelli N., Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: A new prognostic factor?, «DIAGNOSTICS», 2021, 11, pp. 1 - 10 [Articolo in rivista] Open Access

Rosellini M.; Santoni M.; Mollica V.; Rizzo A.; Cimadamore A.; Scarpelli M.; Storti N.; Battelli N.; Montironi R.; Massari F., Treating prostate cancer by antibody-drug conjugates, «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2021, 22, pp. 1 - 15 [Articolo in rivista] Open Access